...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery
【24h】

Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery

机译:在鼻内给药后向大鼠神经系统递送免疫球蛋白G抗体:分布,剂量 - 反应和交付机制

获取原文
获取原文并翻译 | 示例

摘要

The intranasal route has been hypothesized to circumvent the blood-brain and blood-cerebrospinal fluid barriers, allowing entry into the brain via extracellular pathways along olfactory and trigeminal nerves and the perivascular spaces (PVS) of cerebral blood vessels. We investigated the potential of the intranasal route to non-invasively deliver antibodies to the brain 30 min following administration by characterizing distribution, dose-response, and mechanisms of antibody transport to and within the brain after administering non-targeted radiolabeled or fluorescently-labeled full length immunoglobulin G (IgG) to normal adult female rats. Intranasal [I-125]-IgG consistently yielded highest concentrations in the olfactory bulbs, trigeminal nerves, and leptomeningeal blood vessels with their associated PVS. Intranasal delivery also resulted in significantly higher [I-125]IgG concentrations in the CNS than systemic (intra-arterial) delivery for doses producing similar endpoint blood concentrations. Importantly, CNS targeting significantly increased with increasing dose only with intranasal administration, yielding brain concentrations that ranged from the low-to-mid picomolar range with tracer dosing (50 mu g) up to the low nanomolar range at higher doses (1 mg and 2.5 mg). Finally, intranasal pre-treatment with a previously identified nasal permeation enhancer, matrix metalloproteinase-9, significantly improved intranasal [I-125]-IgG delivery to multiple brain regions and further allowed us to elucidate IgG transport pathways extending from the nasal epithelia into the brain using fluorescence microscopy. The results show that it may be feasible to achieve therapeutic levels of IgG in the CNS, particularly at higher intranasal doses, and clarify the likely cranial nerve and perivascular distribution pathways taken by antibodies to reach the brain from the nasal mucosae.
机译:鼻内路线已经假设,以避免血脑和血液 - 脑脊流体屏障,允许沿嗅觉和三叉神经的细胞外途径进入大脑和脑血管的大脑空间(PVS)。通过表征分布,剂量 - 反应和脑内施用非靶向放射性标记或荧光标记的含有荧光标记后,通过表征分布,剂量 - 反应和脑内的抗体输送和脑内的机制,研究了鼻内途径对大脑的鼻内途径对大脑的潜力。长度免疫球蛋白G(IgG)至正常成年女性大鼠。鼻内[I-125] -igg始终如一地在嗅灯泡,三叉神经和百分症血管中产生最高浓度,其与其相关的PVS。在CNS中,鼻内递送也显着提高了CNS的浓度,而不是系统性(动脉内)递送,用于产生类似的终点血液浓度的剂量。重要的是,CNS靶向随着鼻内给药的增加而显着增加,产生从低至中间皮摩尔范围的脑浓度,在较高剂量的低至低纳米摩尔范围内(50μg)(50μg)(1mg和2.5 mg)。最后,用先前鉴定的鼻渗透增强剂,基质金属蛋白酶-9,显着改善鼻内[I-125] -igg递送至多个脑区的鼻内预处理,并进一步使我们阐明从鼻上皮延伸的IgG输送途径进入脑使用荧光显微镜检查。结果表明,在CNS中实现IgG的治疗水平可能是可行的,特别是在较高的鼻内剂量下,并澄清抗体从鼻粘膜到达脑的可能颅神经和血管分布途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号